We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Urine Test Validated for Schistosomiasis

By LabMedica International staff writers
Posted on 16 Jan 2012
Urogenital schistosomiasis in chronically infected adults can be diagnosed by the detection of parasite specific DNA fragments. More...


The sensitivity and specificity of three tests have been evaluated for the viable infection of Schistosoma haematobium in the urogenital tract, which included a polymerase chain reaction hematuria, and the presence of parasite eggs.

A team of collaborating scientists under the auspices of those at Johns Hopkins University (Baltimore, MD, USA) collected over 400 urine samples from adult volunteers in an endemic area in Western Nigeria. These were assessed for hematuria then filtered in the field, the filter papers dried and later examined for eggs and DNA. The results were stratified according to sex and age and subjected to Latent Class analysis.

The DNA was precipitated and concentrated using the Qiagen QIAmp (Qiagen; Germantown, MD, USA) mini- kit. The extracted DNA was used for PCR amplification. The primers were designed to amplify the 121 bp tandem repeat restriction endonuclease from Deinococcus radiophilus (Dra-1) sequence of S. haematobium. Each urine sample was tested with a Hemastix (Bayer; Elkhart, IN, USA) test strip to detect hematuria.

The PCR test indicating the presence of Dra1 DNA fragments in males was 100% for both sensitivity and specificity. This exceeded hematuria with a sensitivity and specificity of 87.6% and 34.7%, respectively, while the detection of eggs, the sensitivity was 70.1% and specificity was 100%. There were similar results for the females except the specificity of the hematuria was 77.0%.

To test the effect of parasite clearance on the persistence of Dra1 fragment, a group of 55 persons who were positive either for presence of parasites eggs and/or DNA in the urine, were followed up two weeks after treatment with praziquantel. Of these 26 (47.3%) were positive for parasite eggs and 42 (76.4%) were positive for DNA. None of these people were positive for eggs or parasite specific DNA in the follow up.

The authors concluded that the molecular test is extremely promising for the diagnosis of urogenital schistosomiasis and should also be useful in field studies as it will be able to reveal infections in people frequently presumed to be uninfected. The PCR test indicated the presence of schistosomes in 10.7% of adults who did not pass eggs in urine specimens. The study was published online on January 3, 2012, in the journal Public Library of Science Neglected tropical Diseases (PLoSNTD).

Related Links:

Johns Hopkins University
Qiagen
Bayer



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.